REDWOOD CITY,
Calif., Sept. 10,
2020 /PRNewswire/ -- AcelRx Pharmaceuticals,
Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on
the development and commercialization of innovative therapies
for use in medically supervised settings, today announced that
management will be providing an overview of the business and
company updates at the H.C. Wainwright & Co. 22nd Annual Global
Investment Conference taking place September
14-16, 2020, and at the Cantor Fitzgerald Virtual Global
Healthcare Conference taking place September
15-17, 2020.
Details of the events are as follows:
H.C. Wainwright & Co. 22nd Annual
Global Investment Conference
Date:
Monday, September 14,
2020
Presentation Time: 4:30 PM Eastern Time / 1:30 PM Pacific Time
Cantor Fitzgerald Virtual Global Healthcare
Conference
Date: Wednesday, September 16,
2020
Presentation Time (Fireside Chat):
4:00 PM Eastern Time / 1:00 PM Pacific Time
A live webcast link of both of the events can be found on
the Company's website at
http://ir.acelrx.com/upcoming-events.
Management will also be hosting one-on-one investor meetings
throughout the day.
For those not available to listen to the live webcast, a
replay will be archived for 90 days and available through the
Investors page on www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for use in medically supervised settings.
AcelRx's proprietary, non-invasive sublingual formulation
technology delivers sufentanil with consistent pharmacokinetic
profiles. The Company has one approved product in the U.S., DSUVIA®
(sufentanil sublingual tablet, 30 mcg), known as DZUVEO in
Europe, indicated for the
management of acute pain severe enough to require an opioid
analgesic for adult patients in certified medically supervised
healthcare settings, and one product candidate, Zalviso®(sufentanil
sublingual tablet system, SST system, 15 mcg) being developed as an
innovatively designed patient-controlled analgesia (PCA) system for
reduction of moderate-to-severe acute pain in medically supervised
settings. DZUVEO and Zalviso are both approved products in
Europe. Zalviso is not approved in
the U.S. For additional information about AcelRx, please visit
www.acelrx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-two-upcoming-conferences-301127962.html
SOURCE AcelRx Pharmaceuticals, Inc.